Citi: Buy Genentech (DNA), Going To $91

Citi analyst Yaron Werber initiates on Genentech (DNA) with a Buy and a $91 target. Werber sees DNA yielding a 14.8% return and is upbeat about growth opportunities given the strength of Genentech’s flagship drug Avestin:

Q2 results showed Avastin reaccelerating due to growth in breast cancer. This is likely sustainable as our oncology survey indicates that penetration in 1st-line breast cancer could grow by 28% in 12 months, while RIBBON-2 data in ’09 could double the penetration in 2nd-line.

Werber also thinks that Avastin will likely be approved for use in colorectal cancer:

Our analysis suggests that Avastin has a 60% chance of showing success in the NSABP C-08 study (data late ’09) based on clean safety, good compliance, and slightly more chemo use in Avastin’s arm.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at

Tagged In